New drug aims to shield patients from harsh chemo side effects
NCT ID NCT06370416
Summary
This study is testing if giving a drug called trilaciclib before standard chemotherapy can protect patients' bone marrow and reduce severe side effects like infections and anemia. It will enroll about 40 adults with advanced non-small cell lung cancer. The main goal is to see if this approach lowers the rate of dangerously low white blood cell counts during treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.